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in culture is bactericidal and should be effective 
for treatment of Crohn’s disease associated 
with Mycobacterium paratuberculosis
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Abstract 
Background: Mycobacterium avium subspecies paratuberculosis (MAP) has been implicated as an etiological agent 
of Crohn’s disease (CD), a debilitating chronic inflammatory bowel disease. Clarithromycin (CLA), clofazimine (CLO), 
rifabutin (RIF) and other antibiotics have been used individually or in combinations with other drugs to treat myco-
bacterial diseases including CD. The treatment has varied by regimen, dosage, and duration, resulting in conflicting 
outcomes and additional suffering to the patients. RHB-104, a drug formula with active ingredients composed of 
(63.3 %) CLA, (6.7 %) CLO, and (30 %) RIF, has been recently subjected to investigation in an FDA approved Phase 
III clinical trial to treat patients with moderate to severe CD. In this study, we determined the efficacy of RHB-104 
active ingredients against MAP strains isolated from the blood, tissue, and milk of CD patients. Based on fluorescence 
quenching technology using the Bactec MGIT Para-TB medium, we determined the minimum inhibitory concentra-
tion (MIC) of CLA, CLO, RIF individually and in dual and triple combinations against 16 MAP clinical strains and 19 
other mycobacteria.
Results: The MIC of all drugs against 35 different mycobacteria ranged between 0.25–20 μg/mL. However, the MIC 
of RHB-104 active ingredients regimen was the lowest at 0.25–10 μg/mL compared to the MIC of the other drugs at 
0.5–20 μg/mL. The components of RHB-104 active ingredients at their individual concentrations or in dual combina-
tions were not effective against all microorganisms compared to the triple combinations at MIC level. The MIC of 
CLA–CLO, CLA–RIF, and CLO–RIF regimens ranged between 0.5–1.25 μg/mL compared to 0.25 μg/mL of bactericidal 
effect of the triple combination.
Conclusion: The data clearly demonstrated that lower concentrations of the triple combination of RHB-104 active 
ingredients provided synergistic anti-MAP growth activity compared to individual or dual combinations of the drugs. 
Consequently, this is favorable and should lead to tolerable dosage that is desirable for long-term treatment of CD 
and Mycobacterium avium complex disease.
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Background
Crohn’s disease (CD), a chronic inflammatory bowel 
disease, is caused by the interplay between genetic 
predisposition, immune dysregulation, and exposure 
to environmental factors. CD affects about 10.7 per 
100,000 people-years in North America [1], and 6.3 
per 100,000 people-years in Europe [2]. Despite the 
low incidence in Asia [3] and Africa, recent epidemio-
logical studies have shown an increasing incidence of 
affected individuals in these continents [4–6]. Patients 
diagnosed with CD suffer from excessive and noctur-
nal diarrhea, abdominal pain, and rapid weight loss, all 
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of which affect their quality of life [7]. A cobblestoned 
appearance of the mucosal layer and granulomas scat-
tered in the distal ileum and colon is observed in CD 
patients [8]. These clinical and pathological manifesta-
tions have been observed in Johne’s disease, a chronic 
granulomatous inflammation of the intestines in rumi-
nants [9]. Johne’s disease is caused by an intracellular 
pathogen called Mycobacterium avium subspecies para-
tuberculosis (MAP), a member of the M. avium com-
plex (MAC) [9]. Our research group has cultured and 
detected MAP from the tissue, milk and blood samples 
from CD patients, showing zoonosis.
Medical treatment of CD includes anti-inflammatory 
drugs, immunosuppressants, nutritional therapy, and 
antibiotics. Anti-inflammatory drugs and immunosup-
presants have been known to alleviate symptoms in 
CD; however, these commonly used medications have 
also been shown to have anti-MAP activity, particularly 
bacteriostatic effects [10]. Monoclonal antibodies such 
as Infliximab (Remicade) and Adalimumab (Humira) 
decrease the pro-inflammatory mediators and cytokines, 
which manages the symptoms experienced by CD 
patients, but relapse occurs after cessation of treatment 
[11–13]. These treatments present with documented sig-
nificant adverse effects that include but are not limited to 
dependency on steroids, hypersensitivity, and potential 
excessive immune suppression leading to susceptibility 
to pathogens [14, 15]. They also do not address the pos-
sible inhibition of MAP as a zoonotic agent in CD, lead-
ing to inadequate treatment. Most often, patients require 
surgical intervention, which includes laparoscopy, stric-
tureplasty, anastomosis, or bypass surgery [16, 17]. These 
surgical procedures are costly and time-consuming, and 
they alter patients’ lifestyles, especially when there is a 
recurrence of CD.
Randomized clinical trials using antibiotic drugs called 
anti-MAP regimen in CD patients have shown promising 
results [18, 19]. Several studies reported that CD patients 
on rifabutin (RIF) and clarithromycin (CLA) regimen 
achieved complete healing of ulcers seen after >6 months 
of treatment. A 2007 case study reported that a patient, 
who was suffering from the recurrence of severe CD and 
was being treated with anti-inflammatory drugs, attained 
complete clinical remission using anti-MAP therapy 
[20]. As shown in Fig. 1, a pill of RHB-104 (RedHill Biop-
harma) active ingredients contains 95 mg CLA (0.63 %), 
10 mg CLO (0.067 %), and 45 mg RIF (0.30 %). The chem-
ical design of RHB-104 formula possesses significant 
potential advantages in drug administration and patient 
compliance. This study is designed to evaluate the active 
ingredients of RHB-104 in  vitro against clinical MAP 
strains from CD patients. An effective anti-MAP therapy 
for CD is vital for clinical evaluation of MAP association 
with CD. Elimination of MAP concurrent with healing 
may result with cure in CD patients.
Methods
Mycobacterial strains and growth conditions
A total of 35 Mycobacterium species were used in this 
study (Table  1). It includes 16 clinical MAP strains, 
which were isolated from different types of clini-
cal specimens from CD patients, 10 Mycobacterium 
avium strains, and 9 other Mycobacterium species. 
Mycobacteria were cultured in BD Bactec™ MGIT™ 
Para-TB medium (Sparks, MD) with growth supple-
ment. Mycobactin J was added to culture media inoc-
ulated with MAP [21]. They were incubated at 37  °C 
and growth was measured initially using the UV illu-
minator (Andromeda). The culture medium contains 
a fluorescent molecule embedded in silicone that is 
sensitive to oxygen and will fluoresce in the presence 
of active respiring mycobacteria. Fluorescence quench-
ing or the absence of fluorescence is indicative of no 
growth. Mycobacterial growth was quantified follow-
ing incubation in a BD Bactec™ MGIT™ 320 Analyzer, 
which measures the intensity of emitted fluorescence 
and converts the value to a measurable growth unit. 
A growth unit of 75 or higher is indicative of bacterial 
growth. The culture media were incubated at 37 °C for 
a total of 6 months.
DNA extraction and IS900 nested PCR analysis
All mycobacterial cultures were subjected to IS900 
nested PCR analysis to confirm their DNA identity. DNA 
Fig. 1 RHB-104 formula
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extraction was followed per protocol as published by our 
group [22]. Nested PCR was performed using P90/P91 
primers (5′-GTTCGGGGCCGTCGCTTAGG-3′/5′-GA 
GGTCGATCGCCCACGTGA-3′) to amplify a 398  bp 
of the IS900 gene in MAP genome. The second prim-
ers for Nested PCR were AV1/AV2 (5′-ATGTGGT 
T G C T G T G T T G G AT G G - 3 ′ / 5 ′ - C C G C C G C A 
ATCAACTCCAG-3′) to amplify a 298  bp from the ini-
tial products. Amplified PCR products were analyzed on 
a 2 % agarose gel [22].
Antibiotic drug susceptibility testing
CLA, CLO, RIF, were kindly provided by RedHill Biop-
harma. The stock solution for CLA at 1 mg/mL was pre-
pared using sodium acetate in water (pH 5.0). The stock 
solution for CLO at 1 mg/mL was prepared using hydro-
chloric acid and sodium dodecyl sulfate in water. The 
stock solution for RIF at 1  mg/mL was prepared using 
absolute methanol [23]. RHB-104 active ingredients 
solution was prepared at a final concentration of 1  mg/
mL by combining the 3 individual dissolved drugs at 
their respective percent composition in RHB-104 (63.3 % 
CLA, 30 % RIF, and 6.7 % CLO; Fig. 1).
The minimum inhibitory concentration (MIC) for each 
drug against mycobacteria was determined by the lowest 
amount of drug tested that completely inhibited bacte-
rial growth indicated by absence of fluorescence from the 
culture tubes, and/or a growth index of zero. All myco-
bacterial strains were inoculated in BD Bactec™ MGIT™ 
Para-TB medium tube with 105–106 colony-forming unit 
in the presence of the drugs at concentrations ranging 
between 0.1–20 μg/mL. Controls were established in cul-
ture medium without any antibiotic drugs. All cultures 
were incubated at 37 °C and read daily for growth for up 
to 6 months.
Synergistic effects analysis
Initially, to determine any synergistic effects of RHB-104 
active ingredients, CLA, CLO, and RIF at their respec-
tive concentrations in MIC levels of RHB-104 were tested 
individually against mycobacterial strains and were com-
pared to CLA–CLO–RIF solutions (Table  2). Bacterial 
resistance or susceptibility to these very low concentra-
tions of CLA, CLO, and RIF was determined. In addition, 
regimens of 2-drug combinations CLA-CLO, CLA-RIF, 
CLO-RIF were also compared to CLA-CLO-RIF solu-
tions. These combinations were prepared at concentra-
tions between 0.1 and 1.0  μg/mL of RHB-104 and used 
against MAP strains cultured in BD Bactec™ MGIT™ TB 
Medium. Growth supplements and culture conditions 
were similar to those in earlier experiments. Percent inhi-
bition of these dual regimens was determined by calcu-
lating bacterial growth index at mid-logarithmic phase in 
culture with the drugs compared to the control without 
any drug.
MAP viability testing
Several culture tubes incubated with MAP and the tri-
ple combination of RHB-104 active ingredients that did 
Table 1 In-vitro activity of  RHB-104 and  its individual 
active ingredients against clinical Mycobacterium strains
CLA clarithromycin, CLO clofazimine, RIF rifabutin, CLA–CLO–RIF mimics RHB-104 
active ingredients solution
Microorganism Minimum inhibitory concentration  
(μg/mL)
CLA CLO RIF CLA–CLO–RIF
Clinical MAP strains
 MAP UCF 3 0.25 1 0.5 0.25
 MAP UCF 4 0.25 0.5 0.5 0.25
 MAP UCF 5 0.25 0.5 0.5 0.25
 MAP UCF 7 1 0.5 0.5 0.25
 MAP UCF 8 1 0.5 0.5 0.25
 MAP UCF 10 10 >10 >10 10
 MAP Strain 1 1 1 1 0.25
 MAP Strain 3 1 1 1 0.25
 MAP Strain 7 1 1 1 0.25
 MAP Strain 8B 1 1 1 0.25
 MAP MS 137 4 4 >6 4
 MAP MS 185 4 6 >6 4
 MAP Para 18 1 >1 >1 0.25
 MAP Ben 1 >1 1 0.25
 MAP Kay 0.5 1 2 0.25
 MAP Linda 0.5 2 0.5 0.25
Non-MAP strains
 M. avium 4 >6 >6 4
 M. avium NEZ >1 >1 >1 >1
 M. avium JF1 >20 >20 >20 >20
 M. avium JF2 >6 >6 >6 >4
 M. avium JF3 >6 >6 >6 >4
 M. avium JF4 >6 >6 >6 >4
 M. avium JF5 >6 >6 >6 4
 M. avium JF6 >6 >6 >6 4
 M. avium JF 7 >6 >6 >6 >4
 M. avium JF8 >6 >6 >6 4
 M. intracellulare LM1-A >6 >6 >6 4
 M. smegmatis >6 >6 >6 6
 M. chelonae >10 10 >10 >10
 M. fortuitum >10 >10 >10 >10
 M. scrofulaceum 10 10 10 10
 M. terrae 10 10 10 10
 M. tuberculosis 10 10 10 10
 M. xenopi 10 10 10 10
 M. vallae 10 10 10 10
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not show signs of bacterial growth following 6  months 
of incubation were investigated for drug effects on MAP 
growth. A volume of 1 mL taken from each culture tube 
was centrifuged at 13,200 rpm for 5 min and the cell pel-
let was washed three times with 1X PBS. Each cell pellet 
was then re-suspended in 800 μL of growth supplement 
including mycobactin J and inoculated into a new tube 
of BD Bactec™ MGIT™ TB Medium. The cultures were 
incubated for 6  months at 37  °C. Tubes were read daily 
for up to 6 months for signs of growth using BD Bactec™ 
MGIT™ 320 instrument.
Results
Confirmation of MAP identity using IS900 nested PCR
IS900 nested PCR was performed on DNA extracts 
from a total of 35 mycobacterial isolates. The detection 
of 298 bp on 2 % agarose gel was reported as MAP posi-
tive. Overall, 16 cultures were identified as MAP and 19 
as other mycobacterial species. Figure  2 shows a repre-
sentative agarose gel for PCR products of some bacterial 
cultures.
Susceptibility of mycobacterial strains to CLA, CLO, RIF, 
and RHB‑104 Active ingredients
The MIC for CLA, CLO, RIF, and RHB-104 active ingre-
dients against 35 mycobacterial strains are shown in 
Table 1. The MIC of each drug ranged between 0.25 and 
2  μg/mL against 13 out of 16 MAP strains. All drugs 
had MIC levels between 4 and  >10 μg/mL for the more 
resistant 3 out of 16 MAP strains, MAP UCF 10, MS 137, 
and MS 185. Interestingly, MAP MS 137 and MS 185 
strains exhibited susceptibility to the triple combination 
Table 2 Susceptibility of  mycobacterial strains to  CLA, CLO, and  RIF at  their concentrations in  the MIC of  CLA–CLO–RIF 
(RHB-104 active ingredients)
MIC minimum inhibitory concentration, CLA clarithromycin, CLO clofazimine, RIF rifabutin, Suscep susceptibility
a MIC was greater than 10 μg/mL and no higher drug concentrations were analyzed
Organism Source MIC Comparison analysis
CLA–CLO–RIF CLA (63.3 %) CLO (6.7 %) RIF (30 %)
μg/mL μg/mL Susceptibility μg/mL Susceptibility μg/mL Susceptibility
Clinical MAP strains
 MAP UCF 3 Tissue 0.25 0.158 R 0.017 R 0.075 R
 MAP UCF 4 Tissue 0.25 0.633 R 0.067 R 0.3 R
 MAP UCF 5 Tissue 0.25 0.633 R 0.067 R 0.3 R
 MAP UCF 7 Tissue 0.25 0.633 R 0.067 R 0.3 R
 MAP UCF 8 Tissue 0.25 0.633 R 0.067 R 0.3 R
 MAP Strain 1 Milk 0.25 0.633 R 0.067 R 0.3 R
 MAP Strain 3 Tissue 0.25 0.633 R 0.067 R 0.3 R
 MAP Strain 7 Tissue 0.25 0.633 R 0.067 R 0.3 R
 MAP Strain 8B Blood 0.25 0.633 R 0.067 R 0.3 R
 MAP MS 137 Tissue 4 2.532 R 0.268 R 1.2 R
 MAP MS 185 Tissue 4 2.532 R 0.268 R 1.2 R
 MAP Para 18 ATCC 19698 0.25 0.633 R 0.067 R 0.3 R
 MAP Ben ATCC 43544 0.25 0.633 R 0.067 R 0.3 R
 MAP Kay ATCC C286 0.25 0.633 R 0.067 R 0.3 R
 MAP Linda ATCC 43015 0.25 0.633 R 0.067 R 0.3 R
Non-MAP strains
 M. avium ATCC 25291 4 2.532 R 0.268 R 1.2 R
 M. avium JF 5 Faeces 4 2.532 R 0.268 R 1.2 R
 M. avium JF 6 Faeces 4 2.532 R 0.268 R 1.2 R
 M. avium JF 8 Blood 4 2.532 R 0.268 R 1.2 R
 M. intracellulare LM1-A Sputum 4 3.798 R 0.402 R 1.8 R
 M-Smegmatis ATCC 27199 6 3.798 R 0.402 R 1.8 R
 M. chelonae subsp. chelonea >10a 6.33 R 0.67 R 3 R
 M. fortuitum subsp. fortuitum >10a 6.33 R 0.67 R 3 R
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of RHB-104 active ingredients at 4.0  μg/mL (contain-
ing 63.3 % CLA—2.53 μg/mL, 6.7 % CLO—0.27 μg/mL, 
and 30  % RIF—1.2  μg/mL) compared to 4 to  >6  μg/mL 
for each of CLA, CLO and RIF, showing some synergistic 
activity of the three active ingredients at lower dosages. 
The MIC of RHB-104 active ingredients for MAP strain 
UCF 10 was 10  μg/mL representing the most resistant 
MAP strain in this study. MAP UCF 10 was resistant to 
CLO and RIF individually at concentrations of  >10  μg/
mL. Although MAP UCF 10 was susceptible to 10  μg/
mL of CLA, it was susceptible to only 6.3  μg/mL when 
CLA was tested as part of RHB-104 active ingredients 
solution. Figure 3 shows 2 representative figures of MAP 
susceptibility to RHB-104 active ingredients, individually 
and in triple combination.
Among non-MAP strains, the MIC values for all drugs 
were higher. The reported MIC for CLA, CLO, RIF, and 
CLA-CLO-RIF among the M. avium strains ranged 
between >1 and  >20 μg/mL. M. avium clinical strain JF1 
showed high resistance with an MIC for all drugs includ-
ing CLA-CLO-RIF at  >20  μg/mL. Non-MAP strains 
such as M. smegmatis, M. chelonae, and M. fortuitum 
were more resistant than other non-MAP strains M. 
scrofulaceum, M. terrae, M. tuberculosis, M. xenopi, and 
M. vallae with reported MIC for all drugs  ≥10  μg/mL 
(Table 1).
Potency of RHB‑104
Although Table 1 showed comparable MIC levels of CLA, 
CLO, RIF, and CLA-CLO-RIF, RHB-104 active ingredi-
ents showed more potency against mycobacterial strains. 
This was determined by further examining each indi-
vidual drug at their concentrations in the MIC levels of 
CLA-CLO-RIF (shown in Table 1) against each respective 
mycobacterial strain. In Table 2, the MIC of CLA–CLO–
RIF against 13 MAP strains was 0.25 μg/mL, which com-
prised 0.158 μg/mL CLA (63.3 % of RHB-104), 0.017 μg/
mL CLO (6.7 % of RHB-104), and 0.075 μg/mL RIF (30 % 
of RHB-104). At these concentrations, MAP showed 
resistance against each of the 3 individual drugs. In two 
other MAP strains (MAP MS 137 and MAP MS 185), all 
individual drugs tested at their concentrations in 4 μg/mL 
CLA–CLO–RIF were not effective at bacterial inhibition. 
In Fig. 3, two representative MAP strains incubated with 
different concentrations of each drug showed the potency 
of RHB-104 even at low dosages.
Non-MAP strains were more resistant to the drugs 
used in this study. The MIC of CLA-CLO-RIF against 
Fig. 2 Nested PCR analysis of DNA from representative mycobacterial cultures. IS900-based nested PCR (nPCR) was performed on DNA extracts 
from MAP and other mycobacterial cultures. PCR products were analyzed on 2 % agarose gel and 298 bp amplified fragment is considered posi-
tive for MAP (lane 20). 1: UCF 5, 2: UCF 8, 3: MAP 7, 4: MAP 8B, 5: MAP Ben, 6: MAP Kay, 7: MAP Linda, 8: MAP Para, 9: MAP UCF 3, 10: MAP UCF 4, 11: 
MAP UCF 5, 12: MAP UCF 7, 13: MAP UCF 8, 14: M. avium JF 7, 15: M. avium JF 8, 16: MAP Para 18, 17: M. avium avium, 18: M. intracellulari LM1A, 19: M. 
smegmatis, 20: M. tuberculosis
Fig. 3 Susceptibility of MAP strains UCF 3 and MS 137 to RHB-104 active ingredients, individually and in triple combination. MGIT para-TB culture 
media supplemented with 2 μg/mL mycobactin J were inoculated with MAP strains UCF 3 and MAP MS 137. In the presence of CLA, CLO, RIF or 
RHB-104 at concentrations ranged between 0 and 6 μg/mL. Culture tubes were incubated at 37 °C for a minimum of 10 weeks. Fluorescence in the 
tube indicated the presence of actively respiring bacteria and an absence of fluorescence indicated lack of bacterial growth
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4  M. avium strains was  4.0  μg/mL  (Table  2). However, 
the individual concentrations of CLA, CLO and RIF in 
4.0  μg/mL of RHB-104 active ingredients solution were 
not effective against M. avium strains (Table 2). Similar 
results were observed when other mycobacteria were 
tested, showing the potency of a the triple combination 
in RHB-104 active ingredients.
Synergistic effects in combined drug therapy
In order to further analyze the synergistic effects of RHB-
104 active ingredients CLA–CLO–RIF, 2-drug combina-
tions were tested against MAP UCF 4 at concentrations 
in RHB-104 ranging from 0.25 to 1.0  μg/mL. As shown 
in Fig. 4, only the triple combination of CLA–CLO–RIF 
completely inhibited (100  % inhibition) MAP growth at 
their concentrations in 0.25  μg/mL RHB-104, whereas 
MAP growth was partially inhibited by CLA–CLO regi-
men at 70  % inhibition and CLA–RIF regimen at 15  % 
inhibition. Moreover, complete inhibition of MAP 
growth for CLA–CLO and CLA–RIF regimens was only 
achieved at higher levels of their concentrations in 0.5 μg/
mL RHB-104. CLO–RIF regimen was the least effective 
against MAP, only inhibiting MAP growth by 90  % at 
their individual concentrations in 1.0 μg/mL of RHB-104.
Bactericidal effect of RHB‑104 active ingredients
Bacterial cell pellet from active culture of MAP UCF 4 
incubated with 1  μg/mL CLA-CLO-RIF solution that 
did not shown signs of growth was washed and re-inoc-
ulated into fresh medium without any drugs. Following a 
6-month incubation, there was no growth in the culture 
tube. The experiment was repeated several times with 
different MAP strains and has resulted in similar out-
comes. The effect of the triple combination of the drugs 
on bacterial cultures could not be reversed. The outcome 
supports a bactericidal effect for the drug in culture.
Discussion
Anti-MAP regimens including CLA, RIF, and CLO 
have been investigated in multiple clinical trials as pos-
sible treatments to many diseases including CD cases 
suspected with MAP implication [24–27]. RHB-104 is a 
new combination anti-MAP therapy that combines these 
three unique drugs in a single pill. In this study, we evalu-
ated in  vitro the efficacy of RHB-104 active ingredients 
against clinical MAP strains and other mycobacterial 
controls.
Initially, we evaluated CLA, CLO, and RIF individu-
ally to determine their potency against 16 clinical MAP 
strains and 19 non-MAP strains. Our data for the MIC 
of each individual drug against MAP were comparable 
to previous studies that reported the MIC for CLA in 
the range between 0.25 and 0.5 μg/mL, CLO at 0.5–1 μg/
mL, and RIF at 0.3–0.5 μg/mL [28–31]. Non-MAP strains 
such as M. smegmatis, M. intracellulare and M. avium 
strains were susceptible at higher dosages of >4 to 20 μg/
mL of CLA, CLO, and RIF which confirmed previous 
studies [32, 33].
The novelty of this study is focused on the efficacy of 
RHB-104 active ingredients solution (CLA–CLO–RIF) 
against 35 microorganisms. This formula has provided 
anti-MAP growth effect at lower concentrations. The 
MIC for RHB-104 active ingredients solution against 
13 out of 16 MAP strains was 0.25 μg/mL (0.158 μg/mL 
CLA, 0.017  μg/mL CLO, and 0.075  μg/mL RIF). Cer-
tainly, CLA at 0.158 μg/mL, CLO at 0.017 μg/mL and RIF 
at 0.075  μg/mL when used individually had no measur-
able effect on MAP growth (Table  2). In fact, we deter-
mined the MIC for CLA, CLO and RIF to be 0.25, 0.5, 
and 0.3 μg/mL, respectively which are multi folds higher 
than their levels in CLA–CLO–RIF solution. Of course, 
some MAP strains required higher MIC for each of these 
drugs (Table 1). Even when these drugs were paired and 
evaluated against MAP, the anti-MAP growth effect was 
not significant compared to that of the triple combina-
tion. As shown in Fig. 4, at 0.25 μg/mL, which is the MIC 
for CLA–CLO–RIF against MAP UCF 4, all possible pair 
combinations of the drugs were no match for the effects 
of the triple combination which makes the active ingre-
dients in RHB-104. The in vitro anti-MAP growth effect 
was the most effective when the triple combination was 
used. The confidence in these data rose from results of 
several lab trials where CLA, CLO and RIF were tested 
individually, in pairs and all together forming RHB-104 
active ingredients. RHB-104 active ingredients CLA–
CLO–RIF also showed potency as a triple combination 
against non-MAP strains. The MIC for CLA–CLO–RIF 
solution against these non-MAP strains ranged between 
4 and 20  μg/mL. However, when CLA, CLO, and RIF 
concentrations at the MIC level in CLA–CLO–RIF 
Fig. 4 Two-drug combinations showed less potency of bacterial 
growth inhibition than triple drug combination. A combination of 
CLA–CLO, CLA–RIF, and CLO–RIF at concentrations of 0.25, 0.5, 0.75, 
and 1 μg/mL were tested against clinical MAP strain UCF 4. The triple 
combination of RHB-104 active ingredients showed effective bacte-
rial growth inhibition at a low MIC level of 0.25 μg/mL, whereas the 
2-drug combinations showed only partial inhibition
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solution were tested, the bacteria continued to grow, 
although not very robustly (or partial growth) as the con-
trol with no added drugs. Partial growth of mycobacte-
ria in the presence of the drug indicates less potency and 
in clinical situations. This could be harmful since it may 
promote acquisition of drug resistance. Overall, our data 
have shown that lower concentrations of CLA–CLO–RIF 
solution, which forms the active ingredients of RHB-104 
provided more efficacious outcomes in vitro against clini-
cal MAP strains and those microorganisms with higher 
MIC values.
While CLA appears to be potent in bacterial inhibition 
at less than 633 or 0.63 μg/mL, it is futile to treat patients 
with one antibiotic drug for several months because of 
possible development of antibiotic resistance. CLA is 
also an inhibitor of CYP34A, an enzyme that is impor-
tant in drug metabolism [34]. Clarithromycin-mediated 
inhibition of CYP34A leads to drug-to-drug interactions 
as well as marked increase of exposure to drugs taken 
chronically such as simvastatin and pravastatin [35–37]. 
A combination of antibiotic drugs such those included in 
RHB-104 can eliminate the problem with drug resistance 
and exacerbated adverse effects while exhibiting effective 
anti-MAP activity.
Conclusion
MAP in humans lack its cell wall [22]; therefore, using 
antibiotic drugs that target cell wall will not only be inef-
ficient for treatment of CD, but it may also lead to com-
plications by inhibiting some normal flora and rise of 
multidrug resistance bacteria. The triple combination of 
CLA, CLO, and RIF in RHB-104 has demonstrated excel-
lent synergistic activity in culture and in inhibition myco-
bacterial growth. RHB-104 should be considered as the 
new generation of CLA, CLO and RIF and may be labeled 
as the new and most effective regimen to treat CD cases 
associated with MAP infection.
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